LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "belimumab" as a keyword



Belimumab use during pregnancy: Interim results of the belimumab pregnancy registry

Sign Up to like & get
recommendations! Published in 2022 at "Birth Defects Research"

DOI: 10.1002/bdr2.2091

Abstract: Belimumab is approved for active, autoantibody‐positive systemic lupus erythematosus (SLE) and lupus nephritis, but limited data exist regarding its use in pregnancy. The Belimumab Pregnancy Registry (BPR, GSK Study BEL114256; NCT01532310) was created to evaluate… read more here.

Keywords: belimumab; pregnancy registry; belimumab pregnancy; pregnancy ... See more keywords

Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada Study

Sign Up to like & get
recommendations! Published in 2017 at "Rheumatology International"

DOI: 10.1007/s00296-017-3682-9

Abstract: To describe the characteristics of patients receiving belimumab, overall patterns of systemic lupus erythematosus (SLE) care, clinical outcomes, and changes in glucocorticoid dose following 6 months of therapy with belimumab, and healthcare resource utilization in belimumab… read more here.

Keywords: clinical outcomes; systemic lupus; lupus erythematosus; study ... See more keywords
Photo from wikipedia

Population Pharmacokinetic and Pharmacodynamic Analysis of Belimumab Administered Subcutaneously in Healthy Volunteers and Patients with Systemic Lupus Erythematosus

Sign Up to like & get
recommendations! Published in 2017 at "Clinical Pharmacokinetics"

DOI: 10.1007/s40262-017-0586-5

Abstract: BackgroundIntravenous belimumab 10 mg/kg every 4 weeks is indicated in patients with active, autoantibody-positive systemic lupus erythematosus receiving standard systemic lupus erythematosus care. Subcutaneous 200-mg weekly administration, which may prove more convenient for patients and improve adherence,… read more here.

Keywords: systemic lupus; belimumab; analysis; lupus erythematosus ... See more keywords

[Lupus erythematosus treatment with belimumab in daily practice: Retrospective study of 15 patients].

Sign Up to like & get
recommendations! Published in 2018 at "Annales de dermatologie et de venereologie"

DOI: 10.1016/j.annder.2017.07.008

Abstract: BACKGROUND Belimumab (an anti-BLyS monoclonal antibody) was recently approved for the treatment of systemic lupus erythematosus (SLE). The aim of the study was to describe efficacy and safety of the drug as well as its… read more here.

Keywords: range; treatment; lupus erythematosus; belimumab ... See more keywords

Efficacité du bélimumab dans les lupus érythémateux cutanés réfractaires : cohorte rétrospective de 8 cas

Sign Up to like & get
recommendations! Published in 2019 at "Annales De Dermatologie Et De Venereologie"

DOI: 10.1016/j.annder.2019.09.162

Abstract: Introduction Le belimumab est un anticorps monoclonal anti-BLyS ayant une indication chez les patients adultes atteints de lupus erythemateux systemique (LES) actif malgre un traitement standard. Nous disposons de peu de donnees sur l’efficacite dans… read more here.

Keywords: atteinte cutanee; belimumab; lesions lupus; les lupus ... See more keywords

Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: A systematic review.

Sign Up to like & get
recommendations! Published in 2017 at "Autoimmunity reviews"

DOI: 10.1016/j.autrev.2017.01.010

Abstract: Both BLISS-52 and BLISS-76 international phase III trials in Systemic Lupus Erythematosus (SLE) met their primary outcomes; however, they were not designed to assess the efficacy of belimumab for the treatment of lupus nephritis (LN).… read more here.

Keywords: systemic lupus; systematic review; lupus erythematosus; efficacy belimumab ... See more keywords

Belimumab slows organ damage progression

Sign Up to like & get
recommendations! Published in 2019 at "Nature Reviews Rheumatology"

DOI: 10.1038/s41584-019-0176-z

Abstract: To assess the efficacy of long-term treatment with belimumab, a post-hoc longitudinal study has used propensity score matching to compare patients from the BLISS long-term extension study who received belimumab (and standard of care) with… read more here.

Keywords: damage progression; belimumab; organ damage; damage ... See more keywords

Effects of telitacicept and belimumab on systemic lupus erythematosus: a systematic review and meta-analysis.

Sign Up to like & get
recommendations! Published in 2025 at "Scientific reports"

DOI: 10.1038/s41598-025-29929-9

Abstract: B cell-targeted therapies play an important role in systemic lupus erythematosus (SLE). Belimumab targets B lymphocyte stimulator (BLyS), whereas telitacicept inhibits both BLyS and APRIL. Although both drugs have demonstrated clinical efficacy in SLE, comparative… read more here.

Keywords: systematic review; response; systemic lupus; belimumab ... See more keywords

Efficacy and safety of belimumab therapy in lupus nephritis: a systematic review and meta-analysis

Sign Up to like & get
recommendations! Published in 2023 at "Renal Failure"

DOI: 10.1080/0886022x.2023.2207671

Abstract: Abstract Background Belimumab is the first biological agent approved for the treatment of systemic lupus erythematosus (SLE), but the efficacy of belimumab for lupus nephritis (LN) is not clear. We conducted this meta-analysis and systematic… read more here.

Keywords: belimumab; meta analysis; therapy; efficacy ... See more keywords

Belimumab for the treatment of pediatric patients with lupus nephritis

Sign Up to like & get
recommendations! Published in 2023 at "Expert Opinion on Biological Therapy"

DOI: 10.1080/14712598.2023.2178297

Abstract: ABSTRACT Introduction The FDA approved the anti-BAFF monoclonal antibody, belimumab, in 2011 for adult systemic lupus erythematosus (SLE), in 2019 for pediatric SLE, in 2020 for adult lupus nephritis (LN), and in 2022 for pediatric… read more here.

Keywords: sle; belimumab; lupus nephritis; systemic lupus ... See more keywords

Examining the safety of belimumab, especially in children: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database.

Sign Up to like & get
recommendations! Published in 2024 at "Expert opinion on drug safety"

DOI: 10.1080/14740338.2024.2430302

Abstract: BACKGROUND Belimumab was approved in the US in 2019 for children with Systemic lupus erythematosus (SLE), making it the only medicine that can treat SLE in both adults and children. The authors retrospectively investigated adverse… read more here.

Keywords: faers database; system; real world; belimumab ... See more keywords